Clinical trial · Observational
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
A Center-Based Chart Review Study to Assess Treatment Outcomes of Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Strategic considerations
Summary
Brief summary (as posted)
Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with AML receiving venetoclax. Data from up to 700 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 10 months. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 10 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Participants Receiving Venetoclax
- description
- Participants with AML receiving venetoclax undergoing chart review.
Primary outcomes (5)
- measure
- Overall Survival (OS)
- timeFrame
- Up to 10 Months
- description
- OS will be measured as the number of days between the initiation of the studied line of therapy and death.
- measure
- Event-free survival (EFS)
- timeFrame
- Up to 10 Months
- description
- EFS will be measured as the number of days between the initiation of the studied line of therapy and disease progression, or refractory disease, or death.
- measure
- Percentage of Participants Achieving Best Overall Response
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * The participant received a diagnosis for acute myeloid leukemia (AML). * The participant was initiated on the studied line of therapy for previously untreated AML, as noted in the protocol. * The participant was treated with the studied line of therapy at least 28 days prior to date of data collection. * Information on the participant's treatments, selected (or important) clinical characteristics, and outcomes is available from the start of the studied line of therapy onwards. Exclusion Criteria: * The participant received the studied line of therapy as part of a clinical trial. * Participant received prior lines of therapy for AML. * The participant has a history of malignancies within 2 years prior to the studied line of therapy, other than AML, and with the exception of what is noted in the protocol.
References
Publications (0)
Data not yet available